{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:39:00Z","timestamp":1789439940173,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007639","name":"Maire Taposen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007639","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008723","name":"Suomen L\u00e4\u00e4ketieteen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.msard.2019.08.005","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T19:27:50Z","timestamp":1565033270000},"page":"221-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Risk of cancer among Finnish multiple sclerosis patients"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6371-2107","authenticated-orcid":false,"given":"Kira","family":"Hongell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samu","family":"Kurki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Liisa","family":"Sumelahti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merja","family":"Soilu-H\u00e4nninen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2019.08.005_bib0001","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10549-004-2229-4","article-title":"Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments","volume":"89","author":"Achiron","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.msard.2019.08.005_bib0002","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.canep.2016.08.018","article-title":"Cancer co-occurrence patterns in Parkinsons disease and multiple sclerosis \u2013 Do they mirror immune system imbalances?","volume":"44","author":"Ajdadic-Gross","year":"2016","journal-title":"Cancer Epidemiol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2019.08.005_bib0003","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jns.2014.02.003","article-title":"HLA-DRB1*15:01 and Epstein-Barr virus in a multiple sclerosis patient with psoriasis, nasopharyngeal and breast cancers. Lessons for possible hidden links for autoimmunity and cancer","volume":"339","author":"Anagnostouli","year":"2014","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2019.08.005_bib0004","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-2007-1019124","article-title":"The immunology of multiple sclerosis","volume":"28","author":"Bar-Or","year":"2008","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.msard.2019.08.005_bib0005","article-title":"2015 Neuroendocrine cell carcinoma of unknown primary arising in long-standing history of multiple sclerosis","volume":"2015","author":"Boussios","year":"2015","journal-title":"Case Rep. Oncol. Med."},{"issue":"6","key":"10.1016\/j.msard.2019.08.005_bib0006","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.msard.2015.08.005","article-title":"Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US department of defense administrative claims database","volume":"4","author":"Capkun","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2019.08.005_bib0007","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/14740338.2017.1346082","article-title":"Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis","volume":"16","author":"Clerico","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"11","key":"10.1016\/j.msard.2019.08.005_bib0008","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.msard.2019.08.005_bib0009","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s40265-017-0814-1","article-title":"Benefit-risk profile of sphingosine-1-phosphate receptor modulators in relapsing and secondary progressive multiple sclerosis","volume":"77","author":"Comi","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2019.08.005_bib0010","article-title":"Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in relapsing-remitting multiple sclerosis: an Italian real-world multicenter experience","volume":"11","author":"D\u00b4Amico","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"5","key":"10.1016\/j.msard.2019.08.005_bib0011","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1177\/1352458514541508","article-title":"Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?","volume":"21","author":"Ellis","year":"2015","journal-title":"Mult. Scler."},{"issue":"18","key":"10.1016\/j.msard.2019.08.005_bib0013","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/09638280500533707","article-title":"Smoking rates and smoking cessation among individuals with multiple sclerosis","volume":"28","author":"Friend","year":"2006","journal-title":"Disabil. Rehabil."},{"key":"10.1016\/j.msard.2019.08.005_bib0014","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jns.2016.09.005","article-title":"Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk","volume":"370","author":"Gaindh","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2019.08.005_bib0015","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","article-title":"Cladribine to treat relapsing forms of multiple sclerosis","volume":"14","author":"Giovannoni","year":"2017","journal-title":"Neurotherapeutics."},{"issue":"10","key":"10.1016\/j.msard.2019.08.005_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165027","article-title":"Risk of premenopausal and postmenopausal breast cancer among multiple sclerosis patients","volume":"11","author":"Hajiebrahimi","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.msard.2019.08.005_bib0017","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing-remitting multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.msard.2019.08.005_bib0018","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2147\/TCRM.S143509","article-title":"Understanding the positive benefit: risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the alemtuzumab clinical development program","volume":"13","author":"Havrdova","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"issue":"9","key":"10.1016\/j.msard.2019.08.005_bib0019","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1212\/WNL.0b013e3181b59c40","article-title":"Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis","volume":"73","author":"Hedstr\u00f6m","year":"2009","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2019.08.005_bib0020","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1177\/1352458515609794","article-title":"Smoking is a major preventable risk factor for multiple sclerosis","volume":"22","author":"Hedstr\u00f6m","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.08.005_bib0021","article-title":"Increased female MS incidence and differences in gender-specific risk in medium- and high-risk regions in Finland from 1981 to 2010","volume":"2013","author":"Holmberg","year":"2013","journal-title":"Mult. Scler. Int."},{"issue":"10","key":"10.1016\/j.msard.2019.08.005_bib0022","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ejmg.2013.07.006","article-title":"Co-occurrence of multiple sclerosis in a BRCA1 positive family","volume":"56","author":"Holzmann","year":"2013","journal-title":"Eur. J. Med. Genet."},{"issue":"4","key":"10.1016\/j.msard.2019.08.005_bib0023","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1177\/1535370214554881","article-title":"Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells","volume":"240","author":"Huang","year":"2015","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.msard.2019.08.005_bib0024","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.toxlet.2017.10.013","article-title":"Anti-inflammatory drug, leflunomide and its metabolite teriflunomide inhibit NSCLC proliferation in vivo and in vitro","volume":"282","author":"Jiang","year":"2018","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.msard.2019.08.005_bib0025","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyv364","article-title":"Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis","author":"Khankanian","year":"2016","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.msard.2019.08.005_bib0026","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1093\/brain\/aws148","article-title":"Cancer risk in multiple sclerosis: findings from British Columbia, Canada","volume":"2012","author":"Kingwell","year":"2012","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.msard.2019.08.005_bib0027","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/jnnp-2013-307238","article-title":"Assessment of cancer risk with \u03b2-interferon treatment for multiple sclerosis","volume":"85","author":"Kingwell","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"issue":"3","key":"10.1016\/j.msard.2019.08.005_bib0028","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ane.12264","article-title":"Incidence of the urological tumors in patients suffering from multiple sclerosis","volume":"130","author":"Krhut","year":"2014","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"10.1016\/j.msard.2019.08.005_bib0029","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1352458510384012","article-title":"Increasing incidence of multiple sclerosis in women in northern Finland","volume":"17","author":"Kr\u00f6kki","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.08.005_bib0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.critrevonc.2015.10.002","article-title":"Cancer specific risk in multiple sclerosis patients","volume":"98","author":"Kyritsis","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.msard.2019.08.005_bib0031","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/1352458511416839","article-title":"No increase in cancer incidence detected after cyclophosphamide in a French cohort of patients with progressive multiple sclerosis","volume":"18","author":"Le Bouc","year":"2012","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2019.08.005_bib0032","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1352458507083625","article-title":"Cancer risk and impact of disease modifying treatments in patients with multiple sclerosis","volume":"14","author":"Lebrun","year":"2008","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2019.08.005_bib0033","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00415-011-5929-9","article-title":"Cancer and MS in the era of disease-modifying treatments","volume":"258","author":"Lebrun","year":"2011","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2019.08.005_bib0034","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40263-018-0564-y","article-title":"Cancer risk in patients with multiple sclerosis: potential impact of disease-modifying drugs","volume":"32","author":"Lebrun","year":"2018","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.msard.2019.08.005_bib0035","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ana.21978","article-title":"Primary infection with the Epstein-Barr virus and risk of multiple sclerosis","volume":"67","author":"Levin","year":"2010","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2019.08.005_bib0036","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1352458514564491","article-title":"A systematic review of the incidence and prevalence of cancer in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2019.08.005_bib0037","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/14740338.2017.1250881","article-title":"Safety of monoclonal antibodies for the treatment of multiple sclerosis","volume":"16","author":"McGinley","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"3","key":"10.1016\/j.msard.2019.08.005_bib0038","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6\u20137","key":"10.1016\/j.msard.2019.08.005_bib0039","doi-asserted-by":"crossref","first-page":"A386","DOI":"10.1016\/j.autrev.2011.11.012","article-title":"Geoepidemiology, gender and autoimmune disease","volume":"11","author":"Moroni","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2019.08.005_bib0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.msard.2017.10.019","article-title":"Common comorbidities and survival in MS: risk for stroke, type 1 diabetes and infections","volume":"19","author":"Murtonen","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2019.08.005_bib0041","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s10072-005-0498-2","article-title":"Multiple sclerosis and lifestyle factors: the Hordaland health study","volume":"26","author":"Nortvedt","year":"2005","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2019.08.005_bib0042","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.msard.2018.12.014","article-title":"Multiple sclerosis and cancer incidence: a Danish nationwide cohort study","volume":"28","author":"N\u00f8rgaard","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1\u20132","key":"10.1016\/j.msard.2019.08.005_bib0043","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jns.2015.06.033","article-title":"Multiple sclerosis and breast cancer","volume":"356","author":"O\u00b4Malley","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2019.08.005_bib0044","article-title":"Multiple sclerosis epidemiology in Finland: regional differences and high incidence","author":"Pirttisalo","year":"2018","journal-title":"Acta Neurol. Scand."},{"issue":"4","key":"10.1016\/j.msard.2019.08.005_bib0045","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1080\/07853890.2018.1461919","article-title":"Adult hospital admissions associated with multiple sclerosis in Finland in 2004-2014","volume":"50","author":"Pirttisalo","year":"2018","journal-title":"Ann. Med."},{"key":"10.1016\/j.msard.2019.08.005_bib0046","unstructured":"Eero Pukkala and Matti Rautalahti, 2013. Cancer in Finland. Publications from the Cancer Society of Finland 2013. ISBN 978-952-5815-16-0, ISBN 978-952-5815-17-7 (pdf). Cancer Society of Finland Publication No. 86, p. 26\u201329."},{"issue":"1","key":"10.1016\/j.msard.2019.08.005_bib0047","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12883-017-0932-0","article-title":"Association between multiple sclerosis, cancer risk and immunosuppressant treatment: a cohort study","volume":"17","author":"Ragonese","year":"2017","journal-title":"BMC Neurol."},{"issue":"10","key":"10.1016\/j.msard.2019.08.005_bib0048","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/jamaneurol.2015.1788","article-title":"Effect of smoking cessation on multiple sclerosis prognosis","volume":"72","author":"Ramanujam","year":"2015","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.msard.2019.08.005_bib0049","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s100720170011","article-title":"The prevalence of multiple sclerosis in the world: an update","volume":"22","author":"Rosati","year":"2001","journal-title":"Neurol. Sci."},{"issue":"7","key":"10.1016\/j.msard.2019.08.005_bib0050","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/ene.12710","article-title":"All-cause mortality following a cancer diagnosis amongst multiple sclerosis patients: a Swedish population based cohort study","volume":"22","author":"Roshanisefat","year":"2015","journal-title":"Eur. J. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2019.08.005_bib0051","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/cam4.1098","article-title":"Melanoma complicating treatment with natalizumab for multiple sclerosis: a report from the southern network on adverse reactions (SONAR)","volume":"6","author":"Sabol","year":"2017","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.msard.2019.08.005_bib0052","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1600-0404.2004.00326.x","article-title":"Occurrence of multiple sclerosis in central Finland: a regional and temporal comparison during 30 years","volume":"110","author":"Sarasoja","year":"2004","journal-title":"Acta Neurol. Scand."},{"issue":"3","key":"10.1016\/j.msard.2019.08.005_bib0053","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1034\/j.1600-0404.2001.103003153.x","article-title":"Increasing prevalence of multiple sclerosis in Finland","volume":"103","author":"Sumelahti","year":"2001","journal-title":"Acta Neurol. Scand."},{"issue":"1","key":"10.1016\/j.msard.2019.08.005_bib0054","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/jnnp.74.1.25","article-title":"Multiple sclerosis in Finland: incidence and differences in relapsing remitting and primary progressive disease courses","volume":"74","author":"Sumelahti","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.msard.2019.08.005_bib0055","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000079947","article-title":"Cancer incidence in multiple sclerosis: a 35-year follow-up","volume":"23","author":"Sumelahti","year":"2004","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10.1016\/j.msard.2019.08.005_bib0056","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/ene.12267","article-title":"Increased breast cancer risk for patients with multiple sclerosis: a nationwide population-based cohort study","volume":"21","author":"Sun","year":"2014","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2019.08.005_bib0057","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrn3464","article-title":"Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders","volume":"14","author":"Tabar\u00e9s-Seisdedos","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.msard.2019.08.005_bib0059","unstructured":"THL Tobacco statistics2017: Health behaviour among the Finnish adult population (AVTK). THL (years 1996-2012). Regional Health and Well-being Study (ATH) (from 2013 onwards). (THL). Health Behaviour and Health among the Finnish Retirement \u2013Age Population (EVTK), THL (years 1997-2011). Regional Health and Well-being Study (ATH) (from 2012 onwards). (THL)."},{"key":"10.1016\/j.msard.2019.08.005_bib0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.msard.2016.10.008","article-title":"Inverse comorbidity in multiple sclerosis: findings in a complete nationwide cohort","volume":"10","author":"Thormann","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"19","key":"10.1016\/j.msard.2019.08.005_bib0061","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1212\/WNL.0000000000001556","article-title":"Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod","volume":"84","author":"Tully","year":"2015","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2019.08.005_bib0062","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.apmr.2007.08.003","article-title":"Smoking among veterans with multiple sclerosis: prevalence correlates, quit attempts, and unmet need for services","volume":"88","author":"Turner","year":"2007","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.msard.2019.08.005_bib0063","unstructured":"www.cancerregistry.fi, the Finnish cancer registry."},{"key":"10.1016\/j.msard.2019.08.005_bib0064","doi-asserted-by":"crossref","unstructured":"\u00c5ivo J. et\u00a0al. Risk of osteoporotic fractures in multiple sclerosis patients in southwest Finland. Acta Neurol. Scand.. 2017 May; 135(5): 516\u2013521. doi: 10.111\/ane.12623. Epub 2016 Jun 22. PMID:27334254.","DOI":"10.1111\/ane.12623"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819303323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819303323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:48:14Z","timestamp":1761900494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819303323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":62,"alternative-id":["S2211034819303323"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.08.005","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of cancer among Finnish multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}